emperor-reduced-heart-failure-toplineresults
Positive, top-line results announced from the EMPEROR-Reduced Phase III trial in adults with chronic heart failure with reduced ejection fraction
Search
EMPRISE-interim-analysis
Interim analysis from EMPRISE real-world study shows decreased risk of hospitalisation for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists
Matthias Muenks
Matthias Muenks, Global Engineering Process and Data Manager, speaks about our innovation and culture.
BI increases commitments to sustainable development
At the World Health Summit 2021, Boehringer Ingelheim announces updates to its strategic approach to sustainable development
clinical-collaboration-with-Amgen
Collaboration to study Boehringer Ingelheim’s SOS1::pan-KRAS Inhibitor in combination with Amgen’s KRASG12C Inhibitor
Stroke Prevention in AF
Stroke Prevention in AF
Outlook for Partnering in Animal Health 2024
Megan Grether, Head of Business Development & Licensing for Animal Health, shares her perspectives on the year ahead for partnering in Animal Health.
InPedILD_trial_enrollment
First patient enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents
Making more health through animal health
Boehringer Ingelheim and Ashoka aim to build a world with a greater access to health for people, animals and their communities.
Life forward - Boehringer Ingelheim company brand
Life forward - Boehringer Ingelheim unveils its evolved company brand
Really Digital, Mr Hach!
The Head of User Experience and SCRUM at Boehringer Ingelheim’s digital lab BI X offers a glimpse into his work and motivation.
Early careers
At Boehringer Ingelheim, we know how important it is to lay the right foundations in your career and build on them with care and support.
Who are we?
Started in 1885 by Albert Boehringer, this independent family-owned company has grown into a top contributor in Human Pharma and Animal Health.
Benefits & Rewards
We invest in our people so they will stay and grow with us. We offer benefits such as rewards and development opportunities to help retain employees.
Financial health
We constantly review our salaries to make sure they stay competitive in each market but we also provide wider support for financial health.
world rabies day 2019
world rabies day 2019
discontinuation-bi-1467335-diabetic-retinopathy
The discontinuation of the development of BI 1467335 in diabetic retinopathy has been announced
Covid Global Support Programm
COVID-19: Boehringer Ingelheim steps up effort with Global Support Program
Boehringer Ingelheim Second Transforming Science Day
World-renowned top scientists and companies in R&D take the stage at Boehringer Ingelheim’s second Transforming Science Day
Health, Safety & Environment
Suppliers shall provide a safe and healthy working environment and shall operate environmentally responsible and sustainable.
Helping smallholder farmers after Covid-19
In Ghana, we are helping smallholder farmers overcome hardship caused by the pandemic.
International Women's Day
We celebrate International Women’s Day with this year’s UN Women motto being “Gender Equality Today for a Sustainable Tomorrow”
Avian influenza prevention at the source
Teshome Mebatsion, Head of Viral Diseases Research at Boehringer Ingelheim, talks about the avian influenza virus, ways of prevention and scenarios for the future.
new_analysis_nintedanib_SSc_ILD
Interim analysis results support long term treatment with nintedanib in SSc-ILD patients
Bees and biodiversity
At Boehringer Ingelheim we attach great importance to sustainable planting on our company site – and to protecting the bees.